Aspirin Metabolites and Mammographic Breast Density in Premenopausal Women.

Abstract

Studies investigating the associations of self-reported aspirin use and mammographic breast density (MBD) have reported conflicting results. Therefore, we investigated the associations of aspirin metabolites with MBD in premenopausal women. We performed this study on 705 premenopausal women who had a fasting blood draw for metabolomic profiling. We performed covariate-adjusted linear regression models to calculate the least square means of volumetric measures of MBD [volumetric percent density (VPD), dense volume (DV), and nondense volume (NDV)] by quartiles of aspirin metabolites [salicyluric glucuronide, 2-hydroxyhippurate (salicylurate), salicylate, and 2,6-dihydroxybenzoic acid]. Approximately 13% of participants reported taking aspirin in the past 12 months. Aspirin users had higher levels of 2-hydroxyhippurate (salicylurate), salicylate, and salicyluric glucuronide (peak area) than nonusers, but only the mean peak area of salicyluric glucuronide was increased by both dose (1-2 tablets per day = 1,140,663.7 and ≥3 tablets per day = 1,380,476.0) and frequency (days per week: 1 day = 888,129.3, 2-3 days = 1,199,897.9, and ≥4 days = 1,654,637.0). Aspirin metabolites were not monotonically associated with VPD, DV, or NDV. Given the null results, additional research investigating the associations of aspirin metabolites in breast tissue and MBD is necessary. Impact: Elucidating the determinants of MBD, a strong risk factor for breast cancer, can play an important role in breast cancer prevention. Future studies should determine the associations of nonaspirin NSAID metabolites with MBD.